Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARAKODA vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
250 mg orally twice daily
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
70-90% (oral); 100% (IV).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Safety and efficacy not established in pediatric patients (<18 years).
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARAKODA vs ALDOCLOR-250, answered by our medical review team.
ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARAKODA and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARAKODA and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.